<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Artemisinin combination therapy (ACT) regimens for treatment of uncomplicated &lt;em&gt;Plasmodium falciparum&lt;/em&gt; malaria in nonpregnant adults and children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Artemisinin combination therapy (ACT) regimens for treatment of uncomplicated <em>Plasmodium falciparum</em> malaria in nonpregnant adults and children</h1>
<div class="graphic"><div class="figure"><div class="ttl">Artemisinin combination therapy (ACT) regimens for treatment of uncomplicated <em>Plasmodium falciparum</em> malaria in nonpregnant adults and children</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup width="25%"></colgroup><colgroup width="15%"></colgroup><colgroup span="2" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Agent</td> <td class="subtitle1">Formulations available</td> <td class="subtitle1">Body weight (kg)</td> <td class="subtitle1" colspan="2">Dose*</td> </tr> <tr> <td rowspan="5">Artemether-lumefantrine<sup>¶</sup><sup>Δ</sup></td> <td rowspan="5">Available as combination tablets containing: <ul class="decimal_heading"> <li>Artemether 20 mg plus lumefantrine 120 mg </li> <li>Artemether 40 mg plus lumefantrine 240 mg </li> </ul> </td> <td> </td> <td colspan="2">Dose administered orally twice daily for 3 days:</td> </tr> <tr> <td>5 to &lt;15</td> <td class="indent1" colspan="2">20 mg plus 120 mg</td> </tr> <tr> <td>15 to &lt;25</td> <td class="indent1" colspan="2">40 mg plus 240 mg</td> </tr> <tr> <td>25 to &lt;35</td> <td class="indent1" colspan="2">60 mg plus 360 mg</td> </tr> <tr> <td>≥35</td> <td class="indent1" colspan="2">80 mg plus 480 mg</td> </tr> <tr> <td rowspan="5">Artesunate-amodiaquine</td> <td rowspan="5">Available as combination tablets containing: <ul class="decimal_heading"> <li>Artesunate 25 mg plus amodiaquine 67.5 mg </li> <li>Artesunate 50 mg plus amodiaquine 135 mg </li> <li>Artesunate 100 mg plus amodiaquine 270 mg </li> </ul> </td> <td> </td> <td colspan="2">Dose administered orally once daily for 3 days:</td> </tr> <tr> <td>4.5 to &lt;9</td> <td class="indent1" colspan="2">25 mg plus 67.5 mg</td> </tr> <tr> <td>9 to &lt;18</td> <td class="indent1" colspan="2">50 mg plus 135 mg</td> </tr> <tr> <td>18 to &lt;36</td> <td class="indent1" colspan="2">100 mg plus 270 mg</td> </tr> <tr> <td>≥36</td> <td class="indent1" colspan="2">200 mg plus 540 mg</td> </tr> <tr> <td rowspan="5">Artesunate-mefloquine</td> <td rowspan="5">Available as combination tablets containing: <ul class="decimal_heading"> <li>Artesunate 25 mg plus mefloquine 55 mg<sup>◊</sup></li> <li>Artesunate 100 mg plus mefloquine 220 mg<sup>◊</sup></li> </ul> </td> <td> </td> <td colspan="2">Dose administered orally once daily for 3 days:</td> </tr> <tr> <td>5 to &lt;9</td> <td class="indent1" colspan="2">25 mg plus 55 mg</td> </tr> <tr> <td>9 to &lt;18</td> <td class="indent1" colspan="2">50 mg plus 110 mg</td> </tr> <tr> <td>18 to &lt;30</td> <td class="indent1" colspan="2">100 mg plus 220 mg</td> </tr> <tr> <td>≥30</td> <td class="indent1" colspan="2">200 mg plus 440 mg</td> </tr> <tr> <td rowspan="5">Artesunate-sulfadoxine-pyrimethamine<sup>§</sup></td> <td rowspan="5">Not available as a fixed-dose combination; available as co-packaged scored artesunate tablets (50 mg) and SP tablets (500 mg sulfadoxine and 25 mg pyrimethamine)</td> <td> </td> <td>Artesunate (orally once daily for 3 days):</td> <td>SP (single dose orally on day 1):</td> </tr> <tr> <td>5 to &lt;10</td> <td class="indent1">25 mg</td> <td class="indent1">250 mg plus 12.5 mg</td> </tr> <tr> <td>10 to &lt;25</td> <td class="indent1">50 mg</td> <td class="indent1">500 mg plus 25 mg</td> </tr> <tr> <td>25 to &lt;50</td> <td class="indent1">100 mg</td> <td class="indent1">1000 mg plus 50 mg</td> </tr> <tr> <td>≥50</td> <td class="indent1">200 mg</td> <td class="indent1">1500 mg plus 75 mg</td> </tr> <tr> <td rowspan="9">Dihydroartemisinin-piperaquine<sup>¥</sup></td> <td rowspan="9">Available as combination tablets containing: <ul class="decimal_heading"> <li>Dihydroartemisinin 20 mg plus piperaquine 160 mg </li> <li>Dihydroartemisinin 40 mg plus piperaquine 320 mg </li> </ul> </td> <td> </td> <td colspan="2">Dose administered orally once daily for 3 days:</td> </tr> <tr> <td>5 to &lt;8</td> <td class="indent1" colspan="2">20 mg plus 160 mg<sup>‡</sup></td> </tr> <tr> <td>8 to &lt;11</td> <td class="indent1" colspan="2">30 mg plus 240 mg<sup>‡</sup></td> </tr> <tr> <td>11 to &lt;17</td> <td class="indent1" colspan="2">40 mg plus 320 mg<sup>‡</sup></td> </tr> <tr> <td>17 to &lt;25</td> <td class="indent1" colspan="2">60 mg plus 480 mg<sup>‡</sup></td> </tr> <tr> <td>25 to &lt;36</td> <td class="indent1" colspan="2">80 mg plus 640 mg</td> </tr> <tr> <td>36 to &lt;60</td> <td class="indent1" colspan="2">120 mg plus 960 mg</td> </tr> <tr> <td>60 to &lt;80</td> <td class="indent1" colspan="2">160 mg plus 1280 mg</td> </tr> <tr> <td>≥80</td> <td class="indent1" colspan="2">200 mg plus 1600 mg</td> </tr> <tr> <td rowspan="8">Artesunate-pyronaridine tetraphosphate<sup>†</sup></td> <td rowspan="8">Available as a combination tablet containing: <ul class="decimal_heading"> <li>Artesunate 60 mg plus pyronaridine tetraphosphate 180 mg </li> <li>Or, for children weighing ≤5 to 20 kg, as an oral suspension of granules from a sachet containing: Artesunate 20 mg plus pyronaridine tetraphosphate 60 mg </li> </ul> </td> <td> </td> <td colspan="2">Dose administered orally once daily for 3 days:</td> </tr> <tr> <td>≥5 to &lt;8</td> <td class="indent1" colspan="2">20 mg plus 60 mg</td> </tr> <tr> <td>8 to &lt;15</td> <td class="indent1" colspan="2">40 mg plus 120 mg</td> </tr> <tr> <td>15 to &lt;20</td> <td class="indent1" colspan="2">60 mg plus 180 mg (use oral suspension)</td> </tr> <tr> <td>20 to &lt;24</td> <td class="indent1" colspan="2">60 mg plus 180 mg (use tablet)</td> </tr> <tr> <td>24 to &lt;45</td> <td class="indent1" colspan="2">120 mg plus 360 mg</td> </tr> <tr> <td>45 to &lt;65</td> <td class="indent1" colspan="2">180 mg plus 540 mg</td> </tr> <tr> <td>≥65</td> <td class="indent1" colspan="2">240 mg plus 720 mg</td> </tr> </tbody></table></div><div class="graphic_lgnd">Most of the dosing regimens listed in this table are consistent with the World Health Organization (WHO) 2022 guidelines for the treatment of uncomplicated <em>Plasmodium falciparum</em> malaria, but may differ from dosing recommended in approved product information. Dosing recommendations for artesunate-pyronaridine tetraphosphate were not included in the WHO guidelines. Product availability varies by locality.</div><div class="graphic_footnotes"><p>SP: sulfadoxine-pyrimethamine; DP: dihydroartemisinin plus piperaquine.</p>
<p>* In general, the course of ACT is administered for three days. In areas of artemisinin resistance, a six-day course of treatment is warranted.</p>
<p>¶ An orally disintegrating flavored tablet is available in some areas. Take after a full meal or whole milk. If patient vomits within 30 minutes of taking a dose, he or she should repeat the dose. Ideally, the first two doses should be taken 8 hours apart.</p>
<p>Δ We select an alternative agent for patients &gt;65 kg; the efficacy of artemether-lumefantrine agent may be diminished as body weight increases.</p>
<p>◊ Mefloquine hydrochloride (55 mg) is equivalent to mefloquine base (50 mg); mefloquine hydrochloride (220 mg) is equivalent to mefloquine base (200 mg).</p>
<p>§ Sulfadoxine-pyrimethamine should be avoided in the first weeks of life because it could aggravate neonatal hyperbilirubinemia.</p>
<p>¥ Piperaquine prolongs the QT interval by approximately the same amount as chloroquine but by less than quinine. DP should not be used in patients with congenital QT prolongation or who are on medications that prolong the QT interval. DP may be taken with food but should not be taken with a high-fat meal. ACTs containing piperaquine should not be used for treatment of malaria acquired in the Mekong subregion (including southwestern Vietnam, western Cambodia, and northeastern Thailand), unless combined with mefloquine.</p>
<p>‡ Children weighing &lt;25 kg treated with dihydroartemisinin-piperaquine should receive a minimum of 2.5 mg/kg body weight per day of dihydroartemisinin and 20 mg/kg body weight per day of piperaquine daily for 3 days.</p>
	
	† If the patient vomits within 30 minutes of taking a dose, he or she should repeat the dose. Mix the required number of sachets of oral suspension with 10 mL of water in a small cup until the granules are suspended evenly and administer immediately. Tablets and the oral suspension may be taken with or without food.</div><div class="graphic_reference">Adapted from:
	<ol>
<li>WHO Guidelines for
		malaria, 18 February 2022. Geneva: World Health Organization; 2022
		(WHO/UCN/GMP/ 2022.01). License: CC BY-NC-SA 3.0 IGO. <a href="https://apps.who.int/iris/handle/10665/351995" target="_blank">https://apps.who.int/iris/handle/10665/351995</a> (Accessed on April 11, 2022).</li>
<li>Pyronaridine tetraphosphate and artesunate. European Medicines Agency (EMA). Summary of product characteristics. Last updated November 7, 2017. European Medicines Agency.</li>
</ol></div><div id="graphicVersion">Graphic 107438 Version 11.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
